Cyclophosphamide and antithymocyte globulin conditioning may be sufficient for Korean patients with early stage severe aplastic anemia transplanted with marrow from donors other than HLA-identical siblings.
We gave a regimen of cyclophosphamide and antithymocyte globulin (CY/ATG) to six patients with early stage severe aplastic anemia (SAA) transplanted with marrow from alternative donors. All patients engrafted and are alive with durable engraftment at a median follow-up of 406 days. The CY/ATG regimen may be sufficient in Korean patients with early stage SAA receiving marrow transplantation from alternative donors.
Lee
J H
JH
Lee
J H
JH
Lee
J S
JS
Kim
W K
WK
Chi
H S
HS
Lee
K H
KH
D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000150:complications / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000008:administration & dosage* / Q000633:toxicity; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000592:standards*; D003520:Cyclophosphamide / Q000008:administration & dosage* / Q000633:toxicity; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000633:toxicity; D007723:Korea; D008297:Male; D014019:Tissue Donors; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000592:standards; D016896:Treatment Outcome
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide